摘要
肠易激综合征(IBS)是一种最常见的胃肠道功能紊乱性疾病,发病率高,给患者带来严重痛苦。IBS的病因和发病机制复杂,目前主要以脑-肠轴异常理论为基础。随着对各种神经递质和受体的深入研究,并以之为靶点,有望得到针对IBS的治疗药物。本文综述了与IBS相关各靶点治疗药物的研究现状、临床疗效及安全性。主要包括以下靶点:5-羟色胺(5-HT)受体、鸟甘酸环化酶C(GC-C)受体、氯离子通道(ClC)、胰高血糖素样肽-1(GLP-1)受体、阿片受体、胆囊收缩素-1(CCK-1)受体、苯(并)二氮类受体等。
Irritable bowel syndrome（IBS） is one of the most common functional gastrointestinal disorders with high prevalence rate,bringing severe financial burdens and psychological pressure to patients.Due to the complicated pathogenesis of IBS,current pathophysiologic mechanisms are based on the abnormalities of brain-gut axis.The continuous reasearches on various neurotransmitters and receptors,designed as targets,are accompanied with a hope of finding new durgs.This review summarizes the research situation,clinical efficacy and safety of various types of IBS new drugs,which includes the following targets：5-hydroxytryptamine receptor,guanylate cyclase C receptor,chloride channel,glucagon-like peptide-1 receptor,opiate receptor,cholecystokinin-1 receptor and benzodiazepine receptor.
出处
《中国药科大学学报》
CAS
CSCD
北大核心
2011年第2期182-188,共7页
Journal of China Pharmaceutical University
